Universität zu Köln

Bakry, Reima, Klein, Med A. and Horneff, Gerd (2022). Oral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis. Eur. J. Rheumatol., 9 (4). S. 197 - 206. SISLI: AVES. ISSN 2148-4279

Full text not available from this repository.

Abstract

Objective: Subcutaneous methotrexate injections are considered to be more effective or work faster than oral methotrexate. Therefore, the extent and the kinetics of response were analyzed in juvenile idiopathic arthritis patients treated with oral versus subcutaneous methotrexate. Methods: The BIKER databank was searched for biologics-naive juvenile idiopathic arthritis patients treated with methotrexate as initial treatment. The Juvenile Arthritis Disease Activity Score-10 definition of remission and the pediatric American College of Rheumatology's response parameters were utilized as outcome criteria. Result: A total of 410 polyarticular juvenile idiopathic arthritis patients receiving oral methotrexate were compared to 384 patients receiving subcutaneous methotrexate. Rheumatoid factor-negative polyarthritis was the most common juvenile idiopathic arthritis category (50%/51%) in this cohort followed by extended oligoarthritis (27%/26%), polyarticular psoriatic arthritis (18%/16%), and few had rheumatoid factor-positive polyarthritis (5%/8%). The oral cohort's disease duration (2.3 +/- 3.0 vs. 1.9 +/- 2.7) was significantly longer (P =.04), although their age at onset and baseline were similar. Furthermore, at baseline, disease activity ( Juvenile Arthritis Disease Activity Score-10 16.5 +/- 7.2 vs. 14.7 +/- 8.2; P =.001 due to a higher active joint count 9.0 +/- 10.1 vs. 7.4 +/- 7.7; P =.011) was higher in the subcutaneous cohort. The weekly methotrexate doses were comparable with 13.6 +/- 5.4 mg/m2 and 13.3 +/- 4.5 mg/m2, respectively. With oral/subcutaneous methotrexate, a pediatric American College of Rheumatology's 90 was achieved in 98(38.3%)/128(40.4%), while 96(38.1 %)/75(40.1%) attained Juvenile Arthritis Disease Activity Score remission after 12 months of therapy. There was no difference in the early kinetics of response according to Kaplan-Meyer analysis. Adverse events including nausea, vomiting, and increased transaminases were considerably more common after methotrexate subcutaneous administration than after oral treatment. Conclusion: In terms of effectiveness, but not safety, our retrospective analysis found some advantages of subcutaneous methotrexate. Adverse effects limit treatment continuance and thus must be considered a disadvantage. Furthermore, oral methotrexate eliminates the need for injections, which is especially essential for younger children. Controlled, randomized prospective trials in children and juvenile patients are necessary for definitive recommendations for the subcutaneous route of administration of methotrexate therapy.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Bakry, Reima UNSPECIFIED UNSPECIFIED UNSPECIFIED Klein, Med A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Horneff, Gerd UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-669986
DOI:	10.5152/eurjrheum.2022.21090
Journal or Publication Title:	Eur. J. Rheumatol.
Volume:	9
Number:	4
Page Range:	S. 197 - 206
Date:	2022
Publisher:	AVES
Place of Publication:	SISLI
ISSN:	2148-4279
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language DISEASE-ACTIVITY; CHILDREN; EFFICACY; CRITERIA; SAFETY; TRIAL Multiple languages Rheumatology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66998